TERIPARATIDE VERSUS ALENDRONATE FOR TREATING GLUCOCORTICOID-INDUCED OSTEOPOROSIS: 36-MONTH RESULTS

被引：0
|
作者：
Devogelaer, J. -P. [1 ]
Warner, M. [2 ]
Saag, K. [3 ]
Zanchetta, J. [4 ]
Adler, R. [5 ]
Eastell, R. [6 ]
See, K. [2 ]
Dalsky, G. [2 ]
Krohn, K. [2 ]
Krege, J. [2 ]
机构：
[1] St Luc Univ Hosp, Arthritis Unit, Brussels, Belgium
[2] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
[3] Univ Alabama, Birmingham, AL USA
[4] IDIM, Buenos Aires, DF, Argentina
[5] McGuire VA Med Ctr, Richmond, VA USA
[6] Univ Sheffield, Acad Unit Bone Metab, Sheffield, S Yorkshire, England
来源：
OSTEOPOROSIS INTERNATIONAL | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：7 / 7
页数：1
相关论文
共 50 条
  • [31] Correlations between bone turnover markers and BMD in patients treated with teriparatide or alendronate for glucocorticoid-induced osteoporosis
    Burshell, A. L.
    Moericke, R.
    Correa-Rotter, R.
    Chen, P.
    Warner, M. R.
    Krege, J. H.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S128 - S128
  • [32] Alendronate for the management of glucocorticoid-induced osteoporosis: Results of the multicenter US study.
    Saag, K
    Emkey, R
    Gruber, B
    Tesser, J
    Lane, N
    Yanover, M
    Dubois, C
    Freedholm, D
    Carofano, W
    Daifotis, A
    ARTHRITIS AND RHEUMATISM, 1997, 40 (09): : 630 - 630
  • [33] COMPARISON OF THE EFFICACY OF DENOSUMAB AND ALENDRONATE IN GLUCOCORTICOID-INDUCED OSTEOPOROSIS
    Iseri, Ken
    Iyoda, Masayuki
    Watanabe, Makoto
    Matsumoto, Kei
    Sanada, Daisuke
    Inoue, Takashi
    Tachibana, Shohei
    Shibata, Takanori
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 : 235 - 235
  • [34] Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment
    Hirooka, Yasuaki
    Nozaki, Yuji
    Inoue, Asuka
    Li, Jinhai
    Shiga, Toshihiko
    Kishimoto, Kazuya
    Sugiyama, Masafumi
    Kinoshita, Koji
    Funauchi, Masanori
    Matsumura, Itaru
    BONE REPORTS, 2020, 13
  • [35] The efficiency and safety of alendronate versus teriparatide for treatment glucocorticoid-induced osteoporosis: A meta-analysis and systematic review of randomized controlled trials
    Liu, Zhi-Ming
    Zhang, Min
    Zong, Yuan
    Zhang, Ding
    Shen, Zhu-Bin
    Guan, Xiao-Qing
    Yin, Fei
    PLOS ONE, 2022, 17 (05):
  • [36] An effect comparison of alendronate and teriparatide in patients with glucocorticoid-induced osteoporosis: A protocol for systematic review and meta-analysis
    Liang, Na
    Zhang, Shuang
    Wang, Shuang
    Ma, Juan
    MEDICINE, 2022, 101 (48) : E32090
  • [37] Consistency of effect of alendronate in glucocorticoid-induced and postmenopausal osteoporosis.
    Ernkey, R
    Saag, K
    Brown, J
    Correa-Rotter, R
    Malice, MP
    Carofano, W
    Dalfotis, A
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S44 - S44
  • [38] Prevention of glucocorticoid-induced osteoporosis with alendronate compared with alphacalcidol.
    de Nijs, RNJ
    Jacobs, WG
    Algra, A
    Buskens, E
    Huisman, M
    de Laet, CED
    Laan, RFJ
    Lems, WF
    Biljlsma, JWJ
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S497 - S497
  • [39] Effect of alendronate on glucocorticoid-induced osteoporosis in Japanese women with systemic autoimmune diseases: versus alfacalcidol
    Takeda, Seiji
    Kaneoka, Hidetoshi
    Saito, Takao
    MODERN RHEUMATOLOGY, 2008, 18 (03) : 271 - 276
  • [40] COST-EFFECTIVENESS OF TERIPARATIDE IN PATIENTS WITH GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN SWEDEN
    Smolen, L. J.
    Gregor, Z.
    Barrett, A.
    Myren, K. J.
    Toll, A.
    VALUE IN HEALTH, 2010, 13 (07) : A308 - A309
12345